Brooke Pereira

Dr. Brooke Pereira

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Trends in Cancer
Verified
Journal Article
Open access
BPBrooke Pereira
Brooke Pereira
CVClaire Vennin
Claire Vennin
MPMichael Papanicolaou
Michael Papanicolaou
CCCecilia R. Chambers
Cecilia R. Chambers
DHDavid Herrmann
David Herrmann
PTPaul Timpson
Paul Timpson
Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, there has been a shift in the field to study CAF subpopulations and the emergent functions of these subsets in tumourigenesis. In this review, we explore how different aspects of CAF heterogeneity are defined and how these manifest in multiple cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC). We also discuss therapeutic approaches to selectively target protumourigenic CAF functions, while avoiding normal fibroblasts, providing insight into the future of stromal targeting for the treatment of PDAC and other solid tumours.

16 June 2021 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
CCCecilia R. Chambers
Cecilia R. Chambers
SRShona Ritchie
Shona Ritchie
BPBrooke Pereira
Brooke Pereira
PTPaul Timpson
Paul Timpson
Senescence is a cellular state in which cells undergo persistent cell cycle arrest in response to nonlethal stress. In the treatment of cancer, senescence induction is a potent method of suppressing tumour cell proliferation. In spite of this, senescent cancer cells and adjacent nontransformed cells of the tumour microenvironment can remain metabolically active, resulting in paradoxical secretion of pro‐inflammatory factors, collectively termed the senescence‐associated secretory phenotype (SASP). The SASP plays a critical role in tumorigenesis, affecting numerous processes including invasion, metastasis, epithelial‐to‐mesenchymal transition (EMT) induction, therapy resistance and immunosuppression. With increasing evidence, it is becoming clear that cell type, tissue of origin and the primary cellular stressor are key determinants in how the SASP will influence tumour development and progression, including whether it will be pro‐ or antitumorigenic. In this review, we will focus on recent evidence regarding therapy‐induced senescence (TIS) from anticancer agents, including chemotherapy, radiation, immunotherapy, and targeted therapies, and how each therapy can trigger the SASP, which in turn influences treatment efficacy. We will also discuss novel pharmacological manipulation of senescent cancer cells and the SASP, which offers an exciting and contemporary approach to cancer therapeutics. With future research, these adjuvant options may help to mitigate many of the negative side effects and protumorigenic roles that are currently associated with TIS in cancer.

12 May 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
GSGeorge Sharbeen
George Sharbeen
JMJoshua A. McCarroll
Joshua A. McCarroll
AAAnouschka Akerman
Anouschka Akerman
CKChantal Kopecky
Chantal Kopecky
JYJanet Youkhana
Janet Youkhana
APand Phoebe A. Phillips
and Phoebe A. Phillips
Cancer-associated fibroblasts (CAF) are major contributors to pancreatic ductal adenocarcinoma (PDAC) progression through protumor signaling and the generation of fibrosis, the latter of which creates a physical barrier to drugs. CAF inhibition is thus an ideal component of any therapeutic approach for PDAC. SLC7A11 is a cystine transporter that has been identified as a potential therapeutic target in PDAC cells. However, no prior study has evaluated the role of SLC7A11 in PDAC tumor stroma and its prognostic significance. Here we show that high expression of SLC7A11 in human PDAC tumor stroma, but not tumor cells, is independently prognostic of poorer overall survival. Orthogonal approaches showed that PDAC-derived CAFs are highly dependent on SLC7A11 for cystine uptake and glutathione synthesis and that SLC7A11 inhibition significantly decreases CAF proliferation, reduces their resistance to oxidative stress, and inhibits their ability to remodel collagen and support PDAC cell growth. Importantly, specific ablation of SLC7A11 from the tumor compartment of transgenic mouse PDAC tumors did not affect tumor growth, suggesting the stroma can substantially influence PDAC tumor response to SLC7A11 inhibition. In a mouse orthotopic PDAC model utilizing human PDAC cells and CAFs, stable knockdown of SLC7A11 was required in both cell types to reduce tumor growth, metastatic spread, and intratumoral fibrosis, demonstrating the importance of targeting SLC7A11 in both compartments. Finally, treatment with a nanoparticle gene-silencing drug against SLC7A11, developed by our laboratory, reduced PDAC tumor growth, incidence of metastases, CAF activation, and fibrosis in orthotopic PDAC tumors. Overall, these findings identify an important role of SLC7A11 in PDAC-derived CAFs in supporting tumor growth. Significance: This study demonstrates that SLC7A11 in PDAC stromal cells is important for the tumor-promoting activity of CAFs and validates a clinically translatable nanomedicine for therapeutic SLC7A11 inhibition in PDAC.

1 July 2019 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
ENElizabeth V. Nguyen
Elizabeth V. Nguyen
BPBrooke Pereira
Brooke Pereira
MLMitchell Lawrence
Mitchell Lawrence
XMXiuquan Ma
Xiuquan Ma
RRRichard J. Rebello
Richard J. Rebello
RDRoger J. Daly
Roger J. Daly
In prostate cancer, cancer-associated fibroblasts (CAF) exhibit contrasting biological properties to non-malignant prostate fibroblasts (NPF) and promote tumorigenesis. Resolving intercellular signaling pathways between CAF and prostate tumor epithelium may offer novel opportunities for research translation. To this end, the proteome and phosphoproteome of four pairs of patient-matched CAF and NPF were characterized to identify discriminating proteomic signatures. Samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with a hyper reaction monitoring data-independent acquisition (HRM-DIA) workflow. Proteins that exhibited a significant increase in CAF versus NPF were enriched for the functional categories “cell adhesion” and the “extracellular matrix.” The CAF phosphoproteome exhibited enhanced phosphorylation of proteins associated with the “spliceosome” and “actin binding.” STRING analysis of the CAF proteome revealed a prominent interaction hub associated with collagen synthesis, modification, and signaling. It contained multiple collagens, including the fibrillar types COL1A1/2 and COL5A1; the receptor tyrosine kinase discoidin domain-containing receptor 2 (DDR2), a receptor for fibrillar collagens; and lysyl oxidase-like 2 (LOXL2), an enzyme that promotes collagen crosslinking. Increased activity and/or expression of LOXL2 and DDR2 in CAF were confirmed by enzymatic assays and Western blotting analyses. Pharmacological inhibition of CAF-derived LOXL2 perturbed extracellular matrix (ECM) organization and decreased CAF migration in a wound healing assay. Further, it significantly impaired the motility of co-cultured RWPE-2 prostate tumor epithelial cells. These results indicate that CAF-derived LOXL2 is an important mediator of intercellular communication within the prostate tumor microenvironment and is a potential therapeutic target. Graphical Abstract Highlights Quantitative (phoshpo)proteome of primary cell cultures of patient-matched prostate CAF and NPF. Key CAF-associated proteins validated using orthogonal methodologies. LOXL2 inhibitors D-penicillamine and PXS-S2A impaired CAF migration and ECM alignment. Pre-treatment with LOXL2 inhibitors impaired migratory capacity of RWPE-2 cells in co-culture.

1 March 2019 in Biomaterials
Verified
Journal Article
Closed access
BPBrooke Pereira
Brooke Pereira
NLNatalie L. Lister
Natalie L. Lister
KHKohei Hashimoto
Kohei Hashimoto
LTLinda Teng
Linda Teng
MFMaria Flandes-Iparraguirre
Maria Flandes-Iparraguirre
EDElena M. De-Juan-Pardo
Elena M. De-Juan-Pardo

1 December 2015 in Current Opinion in Biotechnology
Verified
Journal Article
Closed access
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher
BHBoris Michael Holzapfel
Boris Michael Holzapfel
EDElena M. De-Juan-Pardo
Elena M. De-Juan-Pardo
BPBrooke Pereira
Brooke Pereira
SEStuart John Ellem
Stuart John Ellem
Gail RisbridgerGail Risbridger
Gail Risbridger